Introduction: The Promise of Phage-Derived Platforms

Vaccines remain the most transformative public health intervention in history. From eradicating smallpox to controlling polio and preventing seasonal influenza, vaccines have altered the trajectory of global health. Today, as the world faces persistent infectious threats and the rise of cancer immunotherapy, vaccine science is entering a new era—one powered by virus-like particles (VLPs) and phage-derived scaffolds.

Unlike traditional vaccines, which often rely on attenuated pathogens or recombinant proteins, VLPs harness viral architecture without carrying infectious genomes. This allows them to deliver strong immunogenic signals to the immune system without safety risks. Phage-derived VLPs, in particular, offer unmatched stability, modularity, and scalability. Their robust capsid proteins can be engineered to display epitopes, tumor antigens, or ligands, transforming them into versatile immunogenic platforms for both vaccines and oncology therapies.

At Phage Biologics, we are dedicated to advancing phage-derived VLPs from concept to clinic. As the only CDMO fully specialized in phage platforms, we bring decades of microbial process expertise, phage biology knowledge, and GMP capabilities to vaccine and immunotherapy development. Whether for infectious disease prevention, cancer immunotherapy, or nanoparticle functionalization, our services provide the infrastructure and regulatory alignment needed to transform ideas into clinical solutions.

Applications of Phage-Derived VLPs

Infectious Disease Vaccines

• Broad-Spectrum Immunogens – Phage-derived VLPs provide a robust backbone for displaying viral or bacterial epitopes, inducing strong humoral and cellular responses.
• Pandemic Preparedness – Rapid engineering of VLP scaffolds allows fast response to emerging pathogens such as SARS-CoV-2 variants, influenza strains, or novel zoonotic viruses.
• Durability & Stability – Unlike fragile protein subunits, phage VLPs are thermostable and suitable for low-resource deployment.

Oncology Vaccines & Immunotherapies

• Neoantigen Display – Tumor-specific peptides displayed on phage capsids stimulate potent anti-tumor immunity.
• Combination Immunotherapy – VLP vaccines synergize with checkpoint inhibitors, CAR-T therapies, or cytokine adjuvants.
• Onco-VLP Innovation – Phage-derived particles can be engineered to preferentially target tumor microenvironments.

Nanoparticle Scaffolds

• Functionalized Platforms – VLPs serve as nanoparticles for antigen display, ligand presentation, or targeted delivery.
• Synthetic Biology Expansion – Fusion proteins and engineered capsids allow incorporation of therapeutic payloads.
• Beyond Vaccines – Applications extend to diagnostics, biosensors, and nanotechnology.

Why This Matters

VLPs are no longer experimental—they are a recognized class of safe, potent vaccine scaffolds with commercialized precedents (e.g., HPV and HBV vaccines). By focusing on phage-derived VLPs, we offer a unique, modular platform with superior immunogenicity and scalability.

Capsid Protein Expression

The foundation of phage-derived VLPs lies in the expression of capsid proteins capable of self-assembly.

Our Expression Platforms

• E. coli Expression Systems – High-yield, cost-effective production of capsid proteins under controlled fermentation conditions.
• Yeast Systems (Pichia pastoris, Saccharomyces) – Eukaryotic folding and post-translational modifications for complex constructs.
• Codon Optimization & Gene Design – Tailored expression strategies maximizing solubility and assembly efficiency.
• Host Strain Engineering – Removal of protease pathways and metabolic burden optimizations.

Pilot to GMP Scale

• 2L–50L Pilot Fermentors – For process development and early research-grade VLPs.
• 100L–2000L GMP Fermentors – Industrial scale production for clinical trials and commercialization.

Why It Matters

Phage-derived VLP development fails if capsid proteins cannot be expressed at scale. Our microbial-first expertise ensures reproducible, high-yield expression suited for downstream GMP production.

Controlled Assembly into VLPs

Protein expression is only the first step; controlled assembly is critical to achieve correct structure and immunogenicity.

Assembly Workflows

• In Vitro Assembly – Controlled refolding and assembly protocols to produce uniform VLPs.
• Co-Expression Systems – Simultaneous expression of capsid proteins enabling spontaneous assembly inside host cells.
• Antigen Fusion Strategies – Foreign epitopes genetically fused to capsid proteins for immunogenic display.
• Chemical Conjugation – Post-assembly modification attaching ligands or antigens to VLP surfaces.

Process Control

• Biophysical Optimization – Buffer systems, ionic strength, and pH control to stabilize assembly.
• Kinetic Monitoring – Real-time tracking of assembly via DLS and spectrophotometry.
• Lot-to-Lot Consistency – Assembly SOPs validated to ensure reproducibility.

Why It Matters

Immunogenicity is directly tied to structural integrity. Our assembly systems deliver highly uniform, stable VLPs engineered to maximize immune response.

Analytical Validation

Validation is central to advancing VLPs into preclinical and clinical use.

Core Analytical Services

• Electron Microscopy (EM) – Direct visualization of VLP morphology.
• Dynamic Light Scattering (DLS) – Measurement of particle size distribution and homogeneity.
• Immunogenicity Assays – In vitro and in vivo studies confirming antigen presentation and immune activation.
• Stability Studies – Long-term storage and accelerated degradation studies.
• Genetic Confirmation – Sequencing of fusion constructs and capsid proteins.

Safety Testing

• Endotoxin Reduction – Clearance validated via LAL assays.
• Sterility Testing – GMP-standard microbial testing for release batches.
• Residual DNA Removal – Nuclease treatment ensuring compliance with regulatory thresholds.

Why It Matters

The credibility of VLP vaccines and oncology scaffolds depends on data. Our analytical suite ensures products withstand regulatory and clinical scrutiny.

GMP Production & Fill–Finish

From early research to commercial supply, we provide end-to-end GMP manufacturing capabilities.

GMP Infrastructure

• ISO-Classified Cleanrooms – Built specifically for viral particle production.
• Process Validation – Documentation and reproducibility studies for each manufacturing run.
• QA/QC Integration – Quality embedded in every step, from raw materials to finished vials.

Fill–Finish Services

• Aseptic Vialing – Single-use systems reduce contamination risk.
• Lyophilization Support – Freeze-drying strategies for stability and long-term storage.
• Custom Formulations – Adjuvant integration and buffer optimization for clinical readiness.

Why It Matters

Moving VLPs into the clinic requires not only robust science but also manufacturing credibility. Our GMP platform is purpose-built for phage-derived particles, ensuring regulators and partners trust the product.

Regulatory & Translational Alignment

VLP vaccines and oncology platforms exist in a fast-evolving regulatory space. We align your program with FDA, EMA, and global expectations.

Regulatory Expertise

• CMC Support – IND/IMPD-enabling Chemistry, Manufacturing, and Controls documentation.
• Comparability Studies – Demonstrating batch-to-batch consistency and scalability.
• GMP Compliance – Full adherence to international standards (FDA, EMA, Health Canada, MHRA).

Translational Readiness

• Preclinical Support – Supplying validated material for animal studies.
• Clinical Trial Integration – GMP batches delivered in vials, ready for Phase I/II/III studies.
• Commercial Strategy – Scalable supply ensures smooth transition from trials to launch.

Why It Matters

Regulatory complexity often slows vaccine development. Our integrated alignment reduces delays and positions your program for global approval.

Integrated Development Continuum

Our differentiation lies in providing not just individual services, but a cohesive, end-to-end continuum:

• Discovery → Expression → Assembly → Analytics → GMP Production.
• Reduced Handoffs – Minimizing risk and variability by keeping services in one specialized ecosystem.
• Scalable Engagements – From academic proof-of-concept to multinational clinical supply.

This integration ensures speed, quality, and continuity—crucial in high-stakes vaccine and oncology development.

Why Choose Phage Biologics

1. Phage-Derived Specialization – Unlike generalist CDMOs, our infrastructure is built around phage systems and VLP platforms.
2. Microbial First Expertise – Deep experience in E. coli and yeast expression ensures high-yield capsid production.
3. Advanced Analytics – EM, DLS, and immunogenicity testing confirm clinical readiness.
4. GMP Infrastructure – Purpose-built cleanrooms and aseptic fill–finish systems.
5. Client-Centric Partnerships – Transparent, agile, and collaborative, functioning as an extension of your vaccine program.

Conclusion: Toward the Next Generation of Vaccines

The future of vaccines and oncology therapies demands platforms that combine safety, potency, and scalability. Phage-derived VLPs offer exactly that: viral-level immunogenicity without infectious genomes, modular scaffolding for diverse antigens, and microbial-based production systems that scale to global demand.

At Phage Biologics, we are proud to lead the charge as the first CDMO dedicated exclusively to phage platforms. Our specialization in phage-derived VLPs allows us to engineer, validate, and manufacture immunogenic scaffolds that inspire confidence in regulators, clinicians, and patients alike.

From infectious disease vaccines to oncology immunotherapies, from nanoparticle scaffolds to GMP vials, our services provide the expertise and infrastructure to accelerate your program.

Together, we can move beyond traditional vaccines into a new era of precision immunogenic platforms—delivering solutions for the world’s most urgent health challenges.

Contact our team today at info@phagebiologics.com